Ministry of Science and IC

# COUNTRY REPORT

## of the Republic of Korea

: Focusing on Nuclear Policy & Cancer Radiotherapy

OCT. 31. 2022

## Hyunjoon KWON

Director-General Ministry of Science and ICT Country Report of the Republic of Korea

## Contents



PART 1

New Government's Nuclear Power Policy & Progress



PART 2

Current Status of Cancer Radiotherapy in Korea



PART 3

Contribution to the International Society in Cancer Treatment





Ministry of Science and ICT




## **01** Increasing the Share of Nuclear Power Plants

## Nuclear Power Plants in Korea

- (In operation) 24 units (23,250 MW)
- (Under construction) 4 units (5,600 MW)

## • Increasing Nuclear Power's Share in the Energy Mix


• (2021) 27.4% → (2030) 30% or higher




## • Strengthening Nuclear Power Ecosystem

• Providing a comprehensive support system, encompassing finance, R&D funding, fostering professionals and support for international nuclear bidding

X Establishment of 'Nuclear Power Company Help-desk', etc.



## 02 Strengthening Technological Innovation & Industrial Competitiveness of Korean SMR



For flexibility Boric acid-free operation and flexible operation

## 02

## **Strengthening Technological Innovation** & Industrial Competitiveness of Korean SMR

### **Comparison between SMART and i-SMR**

| Division                            | SMART  | Innovative SMR (i-SMR)  |  |
|-------------------------------------|--|---|--|
| Electrical Output<br>(Total output) | <b>110 Mwe</b><br>(220 MWe)  | 170 Mwe<br>(680 MWe)  |  |
| Core Damage Frequency               | 1.0e-7 /R.·Y or below  | 1.0e-9 /R.·Y or below   |  |
| Fuel Assembly                       | 17×17, 2m, 57 units  | 17×17, 2.4m, 69 units   |  |
| Boric Acid                          | With boric acid  | Without boric acid  |  |
| Control Rod Drive Mechanism         | External   | Built-in  |  |
| Steam Generator                     | Cylindrical, helical   | Spiral, integrated  |  |
| Reactor Coolant Pump                | 4 units (side)   | 8 units (upper)   |  |
| Pressurizer                         | Built-in   | Built-in  |  |
| Reactor Diameter                    | 6 m  | 4.5 m   |  |
| Reactor Length                      | 16 m   | 17 m  |  |
| Reloading Interval                  | 36 months  | 24 months   |  |
| Emergency Core Cooling System       | Passive  | Passive   |  |
| Recirculation Valve                 | -  | Available   |  |
| DC Power                            | Safety grade   | Non-safety grade  |  |
| Secondary Cooling                   | Passive auxiliary feedwater system   | Passive auxiliary feedwater system  |  |
| Containment Vessel Cooling          | Reloading water tank inside the reactor building +<br>Emergency cooling tank | External reactor vessel cooling + Heat exchanger of the passive containment building's cooling system |  |
| Containment Vessel                  | Concrete   | Steel + Concrete  |  |

#### **Strengthening Technological Innovation** 02 & Industrial Competitiveness of Korean SMR

## **Promoting R&D of Generation IV Non-light Water SMR**

- Molten Salt Reactor, MSR Suitable for motive nuclear power system and ship propulsion
- Sodium-cooled Fast Reactor, SFR • Available to meet future demands such as dispersed generation





Ultimate Reactor for Efficient **Carbon-free Applications** 

- (Overview) MSR under development by KAERI
- (Thermal output) 100 MWth
- (Neutron spectrum) High speed
- (Coolant) Chlorine molten salt
- (Outlet temperature) 650°C .
- (Nuclear fuel) High-purity low-enriched uranium
- (Application) Motive power sources (ship propulsion). offshore plants, distributed power supply, hydrogen production, etc.



## SALUS-100

Small, Advanced, Long-cycled and Ultimate Safe SFR

- (Overview) Pool-type SFR under development by KAERI .
- (Thermal output) 267 MWth .
- (Neutron spectrum) High speed .
- (Coolant) Liquid sodium .
- (Outlet temperature) 510°C .
- (Nuclear fuel) Low-enriched uranium metallic fuel .
- (Application) Small-scale heat sources and power . generation

## **03** Enhancing the Safety of NPPs through Technology Development

## • Advancing Prediction, Prevention and Responding Capabilities based on ICT Solutions

- Virtual nuclear reactor for multi-physics simulation and safety evaluation programs for combination of external hazards, etc.
- Predicting, preventing, and responding technologies using AI, digital twin, robots, etc.

Physics-based Digital Twin





## • Commercializing the Uses of Accident-Tolerant Fuel (ATF)

 Significantly increasing safety by improving the quality of pellets<sup>\*</sup> and cladding<sup>\*\*</sup> → Aiming at completing technology development by 2026 and commercialization by 2031

\* (Pellet) UO2 pellets and TRISCO-Sic pellets with improved performance

\*\* (Cladding) Surface-coated ODS Zr-alloy cladding and Fe-based alloy cladding

## Securing Core Technologies for Safe Management of Radioactive Waste

- Establishing an R&D roadmap for high-level radioactive waste\* (2023~2060)
  - \* Publicly announcing core technologies related to high-level radioactive waste treatment, including transport, storage, site, and disposal, domestic technological level, development schedule and method, and budget

### Storage Tank for Spend Nuclear Fuel




## **04** Advancing the Competitiveness and Support System of the Radiation Industry

## O Developing Strategic Radiation Technology

- (Public health & medicine) Developing radioisotopes, radiopharmaceuticals, and particle therapy technology for rare and incurable cancers
- (Industry) Developing equipment and materials for radiation applications intended for flagship industries, including semiconductors and secondary batteries
- (Response to social issues) Developing infectious disease-related technology and radiation technology to reduce plastic waste

## Executing Large-scale R&D Projects via Convergence Clusters

- Setting up convergence clusters to support research/industry/human resource development where large-scale radiation facilities are located
- Executing large-scale R&D projects based on the clusters



# PART 2

# Current Status of Cancer Radiotherapy in Korea



Ministry of Science and ICT



## **01** Developing New Drugs and Pharmaceuticals for Cancer Treatment

## Establishing & Operating the Korea Radioisotope Center for Pharmaceuticals (KRICP)

• (Purpose) Developing radiopharmaceuticals and providing support to the new drug development process by pharmaceuticals\*

\* Including the verification process of safety and validity using radioisotopes

• (Facility) Ultra-sensitive accelerator mass spectrometers, radioisotope-based nonclinical evaluation rooms, clinical test facilities, radiopharmaceutical production facilities, etc.

\* Providing one-stop support, encompassing all stages from pharmaceutical synthesis to imaging evaluation, toxicity evaluation, preclinical trials, and clinical trials, by applying radioisotope-based verification technology in the development process of new drugs



## Developing Disease-specific Radiopharmaceuticals & Transferring to Industry


• Developing radiopharmaceuticals dedicated to the diagnosis and treatment of metastatic breast cancer, radiotherapy enhancers designed for the fluid in the brain and colorectal cancer, etc. → Then, promoting transfer to industry

## **O2** Establishing an Radioisotope Production System for Cancer Treatment

## Securing Radioisotope Production Technology using Medical Cyclotrons

- (Achievements) Secured production technology for eight radioisotopes, including Cu-64, I-124, Zr89, TI-201, and Lu-177 (2017~2022)
  - → Supplying radioisotopes to hospitals and medical research institutes at home and abroad\*

<sup>\* (</sup>Domestic) Ten major hub hospitals, including the Seoul National University Hospital and the Samsung Medical Center (Overseas) University of Singapore



#### Current Status of Cancer Radiotherapy in Korea

## **O2** Establishing an Radioisotope Production System for Cancer Treatment

## • Securing Domestic Production & Mass-production Technology for Major Radioisotopes using Research Reactors and Accelerators

• (With the New Research Reactor) Possible to mass-produce Mo-99, I-131, At-211, Ac-225, etc. at the domestic level




Aerial View of the New Research Reactor

#### **O** Overview of the New Research Reactor

- (Construction period) 2022~2027
- (Thermal Power) 15 MW
- (Fuel/Enrichment/Cladding) U-7Mo/Al-5Si/19.75wt%/Aluminum
- (Utilization) RI production, Neutron Transmutation Doping
- X The target mass-production amount of Mo-99 used for cancer diagnosis has been set to 100,000 curies (Ci), which would account for about 20% of global demand





## **03** Developing New Radiation Technologies for Cancer Treatment

## O Developed the First FLASH Radiotherapy Research System \* in Asia

\* Providing therapeutic performance for cancer equivalent or superior to existing methods by instantaneously emitting high-intensity radiation within one second, while significantly reducing adverse effects on normal tissues

#### Achievements

Developed accelerator and test apparatus capable of FLASH clinical trials for the first time in Asia

#### • Plan

Establishing a FLASH research accelerator and later making it available for use by research institutes in Korea, applying research results to clinical trials and further using in the development of FLASH Radiotherapy Research System equipment \*\* As of now, only five US and five European institutes are capable of FLASH clinical research.

## Reaching Completion of Development of Boron Neutron Capture Therapy (BNCT) System

#### Concept

Injecting Boronophenylalanine (BPA) into the body and then externally irradiating a neutron beam  $\rightarrow$  In the process, cancer tissues are selectively destroyed by the injected boron absorbing thermal neutrons and then engaging in nuclear reactions

#### Achievements

Verified its effectiveness in suppressing tumor growth through tissue and animal efficacy trials in 2021 and going through clinical trials in 2022





FLASH Radiotherapy Research System

#### Current Status of Cancer Radiotherapy in Korea


## **03** Developing New Radiation Technologies for Cancer Treatment

## • Current Status of Radiation Oncology Centers & Devices in Korea

- Radiation Oncology Centers 101 centers in operation
- Devices

## Using a total of 279 radiation treatment devices of 11 different types<sup>\*</sup> either in use or being established

\* Vero, viewray, proton therapy equipment, heavy particle therapy equipment, MR-LINAC, HALCYON, cyber knife, gamma knife, HDR, tomography, LINAC



#### Major Radiotherapy Devices in Korea

| Equipment<br>name                         | #          | Remarks  |
|---|------------|--|
| Heavy<br>particle<br>therapy<br>equipment | 2<br>units | <ul> <li>High cure rates for the three major difficult-to-treat cancers (lung cancer, liver cancer, and pancreatic cancer)</li> <li>Capable of treating almost all types of cancer, except for blood cancer, from early to late stage</li> </ul>   |
| Proton<br>therapy<br>equipment            | 2<br>units | <ul> <li>Applicable to non-metastatic solid cancer with limited affected areas</li> <li>Used to treat cancer in children and adolescents because normal tissues are not damaged</li> </ul>   |
| MR-LINAC                                  | 3<br>units | Linear accelerator combined with MRI   |
| Cyber Knife                               | 8<br>units | <ul> <li>Capable of emitting radiation from different directions<br/>using compact linear accelerators mounted on robot arms</li> <li>Mainly used to treat lung cancer, prostate cancer, liver<br/>cancer, and metastatic spinal cancer</li> </ul> |





# Contribution to the International Society in Cancer Treatment



Ministry of Science and ICT



## **01** Cooperating with International Organizations to Fight against Cancer

## • Cooperating with the IAEA to Join the Efforts in Fighting Cancer

- Providing financial support from the Korean government to the IAEA PACT since 2013
- Planning to make an extrabudgetary contribution to the Rays of Hope initiative in 2022
- Contributing financially to the PACT through voluntary fundraising by the general public since 2007

(Delivered at each year's IAEA General Conference)

## Enhancing the Asian-Pacific Region's Cancer Treatment Capabilities by Leading RCA Projects



Participating in RCA projects in the human health sector as a "Leading Country" over the past ten years
 → Sharing Korea's rich experience and excellent technical expertise in cancer diagnosis and clinical treatment

#### Achievements

Strengthening Stereotactic Body Radiation Therapy for Frequent Cancers of the RCA Region (2016~2019)

- Provided education and training programs for radiotherapy experts to a total of 187 individuals from 16 countries through five regional training sessions
- Seconded experts four times to provide advisory support for radiotherapy, equipment installation and quality control
- Established local network platforms and hubs for radiotherapy education and training in seven countries



Education and training activities conducted through RCA projects in the public health and medicine sector

Contribution to the International Society in Cancer Treatment

## **02** Providing Infrastructure for Cancer Control and Treatment to Major Partners

## Providing Physical & Human Infrastructure Support for Cancer Control and Treatment to Major Partner Countries

 Promoting medical device facilitation, technology transfer, education & training for professionals in connection with R&D support programs and aid projects of the Ministry of Science and ICT.





PET/CT equipment at the center

## **O** Best Practice

## Supported in the Construction and Operation of the National Diagnostic and Treatment Center of Mongolia

#### Contents

Constructed the center and provided necessary equipment\* with education & training

\* Cyclotrons, magnetic resonance imaging (MRI) equipment, computed tomography (CT) equipment, positron emission tomography (PET), etc.

Achievements

**Successfully conducted the first cancer diagnosis imaging\* in Mongolia** \* FDG PET/CT imaging for five cancer patients, including breast cancer patients

Follow-up Cooperation

Signed the international research MOU between Korea-Mongolia for multinational clinical research and conducting Korea-Mongolia joint research for the development of a diagnostic target for PET imaging (KIRAMS)







